Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Accumulated Expenses (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Accumulated Expenses for 7 consecutive years, with $9.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 5.54% to $9.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, up 5.54% year-over-year, with the annual reading at $9.4 million for FY2025, 5.54% up from the prior year.
  • Accumulated Expenses hit $9.4 million in Q4 2025 for Eton Pharmaceuticals, up from $9.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9.4 million in Q4 2025 to a low of $22000.0 in Q2 2021.
  • Historically, Accumulated Expenses has averaged $4.4 million across 5 years, with a median of $4.3 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: crashed 99.33% in 2024 and later surged 18893.75% in 2025.
  • Year by year, Accumulated Expenses stood at $1.4 million in 2021, then skyrocketed by 168.08% to $3.7 million in 2022, then surged by 47.08% to $5.4 million in 2023, then skyrocketed by 65.5% to $8.9 million in 2024, then rose by 5.54% to $9.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for ETON at $9.4 million in Q4 2025, $9.1 million in Q3 2025, and $7.5 million in Q2 2025.